<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362318">
  <stage>Registered</stage>
  <submitdate>28/03/2012</submitdate>
  <approvaldate>30/04/2012</approvaldate>
  <actrnumber>ACTRN12612000468820</actrnumber>
  <trial_identification>
    <studytitle>Capsule endoscopy in the detection of small bowel neoplasias in patients with Lynch syndrome</studytitle>
    <scientifictitle>Patients with Lynch syndrome with an identified mutation in a MMR gene will perform capsule endoscopy to evaluate the prevalence of small bowel neoplasias</scientifictitle>
    <utrn>U1111-1129-5894</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lynch syndrome (Hereditary nonpolyposis colorectal cancer)</healthcondition>
    <healthcondition>Small bowel neoplasia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Small bowel (duodenum and ileum)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Capsule endoscopy will be performed according with standard method:
Small bowel preparation with 2 liters of polyethylene glycol (PEG) preparation. At 5 PM on the evening prior to capsule endoscopy patients will begin drinking an 8-ounce glass of the preparation fluid (in the gallon container) every fifteen minutes until all of the liquid is consumed;

Overnight fast;

Capsule endoscopy (Mirocam) will be swallowed in the day of the exam and pictures will be taken for 12 h and collected in a recorder. The capsule is eliminated in the feces and does not need to be recovered.
The images are read in the appropriate software by an experienced physician.</interventions>
    <comparator>Not applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To access the prevalence of small bowel neoplasias in patients with Lynch syndrome using capsule endoscopy findings. 
Patients with relevant findings at capsule endoscopy- tumours or polyps, will be submitted to upper GI endoscopy or double ballon enetroscopy for histological confirmation.</outcome>
      <timepoint>At the time that capsule endoscopy is performed</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Mismatch repair gene mutation;
Give written informed consent;
More than 40 years of age</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>GI occlusive symptoms;
unexplained weight loss in the last 2 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>9/05/2012</anticipatedstartdate>
    <actualstartdate>9/05/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>59</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>-</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Instituto Portugues de Oncologia de Lisboa. EPE</primarysponsorname>
    <primarysponsoraddress>R. prof. Lima Basto 1099-023 Lisbon</primarysponsoraddress>
    <primarysponsorcountry>Portugal</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Instituto Portugues de Oncologia de Lisboa. EPE</fundingname>
      <fundingaddress>R. prof. Lima Basto 1099-023 Lisbon</fundingaddress>
      <fundingcountry>Portugal</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The cumulative risk of small bowel neoplasias in patients with Lynch syndrome (LS) is of 4% (100 times higher than that of the normal population).
Small bowel surveillance in patients with LS is not recommended in surveillance guidelines.
Recent data from a study with a small number of patients capsule endoscopy detected small bowel neoplasias in 8,5% of asymptomatic patients with LS.
We intend to perform a prospective observational uncontrolled study in asymptomatic LS patients older than 40 years. The main endpoint of the study is to access the prevalence of small bowel neoplasias using capsule endoscopy.
All capsules will be read independently by two observers. All lesions detected will be evaluated by the two observers and a consensus will be reached. 
All patients with lesions considered to be relevant and related to the LS (polyps or tumours) will be submitted to double balloon endoscopy to evaluate the lesion and to obtain a specimen for histological examination.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethis Committee from the IPOLFG.EPE</ethicname>
      <ethicaddress>R. prof. Lima Basto
1099-023 Lisbon</ethicaddress>
      <ethicapprovaldate>20/12/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Portugal</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Susana Mao de Ferro</name>
      <address>Gastroenterology department - Instituto Portugues de Oncologia de Lisboa Dr Francisco Gentil 1099-023 Lisbon</address>
      <phone>+351935924759</phone>
      <fax>+351217229855</fax>
      <email>smaodeferro@gmail.com</email>
      <country>Portugal</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Susana Mao de Ferro</name>
      <address>Gastroenterology department - Instituto Portugues de Oncologia de Lisboa Dr Francisco Gentil 1099-023 Lisbon</address>
      <phone>+351935924759</phone>
      <fax>+351217229855</fax>
      <email>smaodeferro@gmail.com</email>
      <country>Portugal</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Susana Mao de Ferro</name>
      <address>Gastroenterology department - Instituto Portugues de Oncologia de Lisboa Dr Francisco Gentil</address>
      <phone>+351935924759</phone>
      <fax>+351217229855</fax>
      <email>smaodeferro@gmail.com</email>
      <country>Portugal</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Susana Mao de Ferro</name>
      <address>Gastroenterology department - Instituto Portugues de Oncologia de Lisboa Dr Francisco Gentil 1099-023 Lisbon </address>
      <phone>+351935924759</phone>
      <fax />
      <email>smaodeferro@gmail.com</email>
      <country>Portugal</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>